|
🐢
|
IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.
R. Thomas,
S. Halim,
S. Gurudas,
S. Sivaprasad,
David R. Owens
|
8 |
2019 |
8
🐢
|
|
🐢
|
The application of simple metrics in the assessment of glycaemic variability.
L. Monnier,
C. Colette,
David R. Owens
|
6 |
2018 |
6
🐢
|
|
🐢
|
Insulin and atherosclerosis: how are they related?
L. Monnier,
Markolf Hanefeld,
O. Schnell,
C. Colette,
David R. Owens
|
5 |
2013 |
5
🐢
|
|
🐜
|
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
10 auth.
Per-Henrik Groop,
Per-Henrik Groop,
S. D. Prato,
M. Taskinen,
David R. Owens,
Y. Gong,
...
Susanne Crowe,
Sanjay Patel,
M. Eynatten,
H. Woerle
|
5 |
2014 |
5
🐜
|
|
🐢
|
Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend.
L. Monnier,
C. Colette,
J. Schlienger,
B. Bauduceau,
David R. Owens
|
4 |
2019 |
4
🐢
|
|
🐢
|
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
L. Monnier,
C. Colette,
Sylvie Dejager,
David R. Owens
|
4 |
2016 |
4
🐢
|
|
🐬
|
The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.
L. Monnier,
David R. Owens,
G. Bolli
|
3 |
2016 |
3
🐬
|
|
🐢
|
Edinburgh Research Explorer Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus
B. Frier,
W. Landgraf,
Mei Zhang,
G. Bolli,
David R. Owens
|
0 |
2018 |
0
🐢
|
